A PHASE 1, MULTICENTER, OPEN-LABEL, DOSEESCALATING SAFETY STUDY OF HUMAN CORD BLOOD DERIVED, CULTURE EXPANDED NATURAL KILLER CELL (PNK-007) INFUSION WITH SUBCUTANEOUS RECOMBINANT HUMAN IL-2 (RHIL-2) IN ADULTS WITH RELAPSED AND/OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) - Regional Cancer Care Associates LLC

Clinical Trials

A PHASE 1, MULTICENTER, OPEN-LABEL, DOSEESCALATING SAFETY STUDY OF HUMAN CORD BLOOD DERIVED, CULTURE EXPANDED NATURAL KILLER CELL (PNK-007) INFUSION WITH SUBCUTANEOUS RECOMBINANT HUMAN IL-2 (RHIL-2) IN ADULTS WITH RELAPSED AND/OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

Type of Cancer
Leukemia
Locations
Hackensack
Sponsor
Celgene
Protocol Number
CCT-PNK-007-AML-001
Cancer Diagnosis
To Learn More Call
201-510-0910